Literature DB >> 1981108

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients.

G Cassens1, A K Inglis, P S Appelbaum, T G Gutheil.   

Abstract

We have reviewed the literature from the 1950's to the present on the effects of neuroleptics on perceptual and neuropsychological function in chronic schizophrenic patients. In contrast to previous reviews, we have delineated the acute and chronic effects of neuroleptics on individual cognitive and motor tasks by drug, dose, and length of administration. To date, studies have shown that acute administration of neuroleptics impairs performance on some, but not all, tasks requiring vigilance and attention, and on some tasks requiring motor behavior. Chronic administration of neuroleptics, however, improves performance on some tasks requiring sustained attention and visuomotor problem-solving skills depending on dose and length of administration. Moreover, there is consistent evidence to suggest that chronic administration of neuroleptics in this patient population does not impair neuropsychological function independent of motor function. These findings have direct implications regarding the risk/benefit ratio and legal ramifications for the use of neuroleptics in chronic schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981108     DOI: 10.1093/schbul/16.3.477

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  29 in total

Review 1.  Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.

Authors:  S E Purdon
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Cognitive effects of olanzapine treatment in schizophrenia.

Authors:  Susan R McGurk; M A Lee; K Jayathilake; Herbert Y Meltzer
Journal:  MedGenMed       Date:  2004-05-10

Review 3.  Psychomotor slowing in schizophrenia.

Authors:  Manuel Morrens; Wouter Hulstijn; Bernard Sabbe
Journal:  Schizophr Bull       Date:  2006-11-08       Impact factor: 9.306

Review 4.  Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.

Authors:  William S Stone; Larry J Seidman
Journal:  Schizophr Bull       Date:  2007-05-15       Impact factor: 9.306

5.  Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study.

Authors:  Shelly L Babin; Ashley J Hood; Adel A Wassef; Nina G Williams; Saumil S Patel; Anne B Sereno
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-06-13       Impact factor: 5.067

Review 6.  Treating cognitive dysfunction in patients with schizophrenia.

Authors:  C A Galletly; C R Clark; A C MacFarlane
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

7.  Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients.

Authors:  Yoram Braw; Yuval Bloch; Shlomo Mendelovich; Gideon Ratzoni; Gilad Gal; Hagai Harari; Asaf Tripto; Yechiel Levkovitz
Journal:  Schizophr Bull       Date:  2007-11-05       Impact factor: 9.306

8.  Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.

Authors:  S Kristian Hill; John A Sweeney; Robert M Hamer; Richard S E Keefe; Diana O Perkins; Hongbin Gu; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  J Int Neuropsychol Soc       Date:  2008-03       Impact factor: 2.892

Review 9.  What do we know about neuropsychological aspects of schizophrenia?

Authors:  Barton W Palmer; Sharron E Dawes; Robert K Heaton
Journal:  Neuropsychol Rev       Date:  2009-07-30       Impact factor: 7.444

10.  The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.

Authors:  Gabriel Selva-Vera; Vicent Balanzá-Martínez; José Salazar-Fraile; José Sánchez-Moreno; Anabel Martinez-Aran; Patricia Correa; Eduard Vieta; Rafael Tabarés-Seisdedos
Journal:  BMC Psychiatry       Date:  2010-06-15       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.